FDA approves Sanofi and Regeneron's skin cancer med

Oct 02, 2018

Libtayo, the skin cancer drug made by Sanofi and Regeneron, has been approved by the U.S. Food and Drug Administration.

The med is used to treat metastatic cutaneous squamous cell carcinoma, a rare skin cancer, in patients whose condition have not improved following surgery or chemotherapy.

Sanofi Genzyme and Regeneron will market the drug jointly in the U.S., selling at a list price of $9,100 for a three-week treatment cycle.

Read the Reuters report

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments